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PP-083 The relationship between HBV precore region
mutation and the variation of T-lymphocyte
subpopulations in patients with chronic
hepatitis B
Jing You*,1, Xu Zhang1, Lin Zhuang2, Hong-Ying Chen1,
Bao-Zhang Tang1, Qing-Qing Wang1, Li Chen1. 1Department of
Infectious Diseases, The First Afﬁliated Hospital of Kunming
Medical University; 2Department of Hepatopathy, Third
Municipal People’s Hospital of Kunming
Objective: To investigate peripheral T-lymphocyte subpopulation
proﬁle and its correlation with HBV precore region 1896 mutation
in patients with chronic hepatitis B.
Methods: HBV precore region 1896 mutation and distribution of
T-lymphocyte subpopulations in peripheral blood were measured
in 65 CHB patients. HBV markers were detected with ELISA.
Serum HBV DNA load was assessed with quantitative real-time
polymerase chain reaction (PCR). The relationship between pre-
core mutation and variation in peripheral T-cell subsets was
analyzed.
Results: CHB patients had signiﬁcantly decreased CD3+ and CD4+
cells and CD4+/CD8+ ratio, and increased CD8+ cells compared
with unifected controls, all with P<0.001. Comparing with HBV
precore region non-mutation group, the patients with precore
mutation had signiﬁcant decreased CD4+ cells and CD4+/CD8+ ra-
tio and increased CD8+ cells. Univariate analysis showed a similar
pattern of these parameters was signiﬁcantly associated with
presence of serum HBeAg expression and high viral load, all with
P<0.05 or 0.01. The presence of HBeAg expression and quantities
of HBVDNA carried by the HBV precore region mutation positive
group were not signiﬁcant different than those observed in HBV
precore region mutation negative group. No obvious differences
of T-cell parameters and presence of precore mutation were
observed among various age groups and sex groups.
Conclusion: T-lymphocyte failure was signiﬁcantly associated
with HBV precore region mutation in CHB patients. Which with
HBeAg expression and the HBV DNA replication affect each
other and co-result in lower T-cell immune function and chronic
infection persistent status.
PP-084 Relationship between plasma thrombin
activatable ﬁbrinolysis inhibitor (TAFI) and
chronic hepatitis
Chengwei Xu1, Lei Wang*,2. 1Department of Laboratory
Medicine, 2Department of Infectious Diseases, The Second
Hospital of Shandong University
Background and objective: Thrombin activatable ﬁbrinolysis in-
hibitor (TAFI), a member of the metallo-carboxypeptidase family,
is a protein enzymogen that is secreted from liver and trans-
ported to plasma. TAFI is a coagulation and ﬁbrinolysis regulator
that generates an important complement to the classical coag-
ulation and ﬁbrinolysis pathways. The aim of this article is to
investigate the changes of plasma TAFI and its clinical signiﬁ-
cence in patients with chronic hepatitis B and hepatocirrhosis.
Methods: All 120 patients with chronic hepatitis B of different
stage and liver cirrhosis and 60 normal control were recruited.
1.8ml limosis elbow vein blood was collected from patients and
controls. The blood was anti-coagulated by adding 0.2 ml sodium
citrate, followed by mixing and centrifugation at 3000 rpm for 15
min. Platelet-poor plasma was then taken, aliquoted and stored
at -70° for detection of TAFI concentration. Chromogenic assays
were used to measure the TAFI activity (TAFI Act) and ELISA
method to TAFI antigen (TAFI Ag).
Results: Plasma TAFI Act and TAFI Ag is 26.4±6.5μg/ml and
83.2±25.8% respectly in normal control group. Plasma TAFI Act
and TAFI Ag in patients with chronic hepatitis B (moderate and
severe stage) and hepatocirrhosis were signiﬁcently lower than
those in control group (P<0.05 or P<0.01).
Conclusion: TAFI can repress the ﬁbrinolytic system.With the
damage of liver function, there is cogulation hypofunction and
ﬁbrinolysis hyperfunction and hemorrhagic tendency ensued. To
test plasmaTAFI can be as a valuable predictor for dignosis and
treatment and prognosis of chronic hepatitis B and liver cirrhosis.
PP-085 Prevalence of occult HBV infection in the
Province of Tehran, Iran
Mohammad Mehdi Attarpour Yazdi *. Department of
Microbiology, Faculty of Medicine, Shahed University, Tehran,
Iran
Background: Occult hepatitis B is deﬁned by the presence of HBV
DNA in serum or liver in the absence of HBsAg. Low serum HBV
DNA titers, in the range of 100 to 1000 copies/ml, are typical in
occult HBV infection. HBV infection can lead to chronic disease,
cirrhosis and liver cancer. For this reason the aim of this research
was to ﬁnd out the prevalence of occult HBV infection in Tehran
(Iran).
Methods: The methodology used in this research is a semi-
experimental one. The research was conducted on 250 patients.
HBsAg, anti-HBs and anti-HBc quality was tested by ELISA method
and HBV DNA quantiﬁcation was tested by real-time PCR assay in
2007 (Tehran).
Results: 130 of 250 patients were HBsAg and HBV DNA positive.
7 of 120 HBsAg-negative patients had HBV DNA positive. Occult
HBV infection rate was 5.83%.
Conclusion: We found that prevalence rate of occult HBV in-
fection tends to correlate with intermediated prevalence of
hepatitis B infection in Tehran (Iran). Occult HBV infection rate
range between 7% to 13% in the world.
PP-086 Enhancement of immune responses to HBsAg by a
multi-copy CpG ODN-contained plasmid
Ping Zhao1, Yi-min Tong1, Zhi-hui Chen*,2, Zhong-tian Qi 1.
1Department of Microbiology, Second Military Medical
University, Shanghai, China; 2Department of Infectious
Diseases, Changhai Hospital, Second Military Medical University,
Shanghai, China
Objective: To explore the possibility of using plasmid containing
muti-copies of CpG ODN as adjuvant for therapeutic vaccine
against hepatitis B.
Methods: A kind of plasmid pKO-CG6, containing six copies of
D type CpG ODN was constructed. This plasmid and the carrier
plasmid pKO were used to stimulate peripheral blood monouclear
cells (PBMC) of healthy or HBV infected persons, and prolifera-
tion response and secretion of IFN-γ and IL-12 were detected.
Further, Recombinant HBsAg was formulated with each of the
both plasmids and used to immunize BALB/c mice and immune
responses to HBsAg were assayed.
Results: Plasmid pKO-CG6 could activate PBMC of healthy or HBV
infected persons and enhance the production of IFN-γ and IL-12
more efﬁciently than carrier vector pKO in vitro. Although vector
pKO could act as immunological adjuvant for HBsAg in mice,
plasmid pKO-CG6 elicited much more stronger immune responses
to HBsAg, especially for cell-mediated response.
Conclusion: Plasmid containing multi-copies of CpG ODN could
excite PBMC of HBV infected persons and enhance the immune
responses to HBsAg in mice, which indicated this method may be
potential value for therapeutic vaccine against hepatitis B.
